Project description
European hub to improve EU healthcare and innovation
Many healthcare innovations and solutions often enter the market at a cost that is unaffordable for the majority of patients. The extended periods of development and production further impede their potential benefits and their capacity to assist patients. With this in mind, the EU-funded EHAB project seeks to expedite the delivery and advancement of novel health techniques and products. Its objectives include enhancing patient access to these innovations, facilitating the development of novel biomaterials and techniques, and promoting collaboration among EU SMEs. To realise these goals, the project will establish an interconnected European value chain and powerhouse dedicated to increasing patient access to innovative therapies, fostering collaboration among EU SMEs, identifying weaknesses in the European region and devising effective solutions.
Objective
The ultimate goal of EHAB is to accelerate the delivery of innovative health techniques and products, in the area of advanced therapies/regenerative medicine and biomaterials to citizens and patients who need it. This innovative healthcare should be affordable for all and improve the quality of life of patients. With Advanced Therapies & Biomaterials it will be possible to have more effective and efficient healthcare for lots of common diseases, like orthopedics, cancer or cardiovascular. Currently it is very hard to bring these techniques to the market and companies face many barriers, from production challenges to regulation. Joint action at an EU level can make the difference. Ecosystems can work together to overcome the barriers of the companies to catalyze and speed up the process of bringing innovative AT&B products to the market. The first step in creating this value chain is to capitalize and connect the assets with EU innovation ecosystems and lay the foundation for an excellent partnership from different European regions.
EHAB’s Vision is thus to strengthen the European landscape in advanced therapies and biomaterials (AT&B) by building a European interconnected value chain and powerhouse to making cell and tissue related therapies available to all European citizens, seizing opportunities in key parts of the AT&B value chain, consolidating EU assets, notably SMEs and increasing its international competitiveness.
EHAB’s Mission is to identify regional strengths, weaknesses, gaps and needs in a joint transregional AT&B value chain and to elaborate an action plan to strengthen the performance and capacity of the innovation ecosystems, their efficient interconnection and their alignment towards EU-level priorities, jointly tackling challenges at EU, national and regional level together with the quadruple helix stakeholders from the deeptech SME community, funding agencies, investors, academia, service providers, notified bodies, policy makers, patients.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicineoncology
- engineering and technologyindustrial biotechnologybiomaterials
You need to log in or register to use this function
Keywords
Programme(s)
Funding Scheme
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinator
5026 PB Tilburg
Netherlands